About Entrechem  >  Scientific Collaborators

the company   ı   founders   ı   key personnel   ı   scientific collaborators   ı   business consultants

EntreChem has built a network of selected scientific collaborators in Europe and the USA, including chemists, biochemists and oncologists. Below, in alphabetical order, a list of collaborators already co-authors of papers and posters with EntreChem.

Carlo V. Catapano, M.D., Ph.D.

Carlo V. Catapano is the Director of Institute of Oncology Research (IOR) and Head of the Tumor Biology and Experimental Therapeutics Program in Bellinzona, Switzerland.

He received his MD from the University of Naples, Italy, and his PhD in Biochemistry from Wake Forest University (WFU) in Winston-Salem, North Carolina, USA. He trained in medical oncology at the University of Naples, in cancer pharmacology at the Mario Negri Institute for Pharmacological Research in Milan, Italy, and later in biochemistry and molecular biology at WFU. From 1993 he was a faculty at the Medical University of South Carolina (MUSC; Depts of Experimental Oncology, Biochemistry and Molecular Biology, and Medicine) and at the Hollings Cancer Center, Center for Molecular and Structural Biology, and the Laboratory of Cancer Genomic in Charleston, SC, USA.

From 2003 he has been the Director of the Laboratory of Experimental Oncology of the Oncology Institute of Southern Switzerland (IOSI) and since 2010 of the IOR. Research in his group focuses on development of new therapeutics with a major emphasis on targeting transcription factors, epigenetic regulators and non-coding RNAs in cancer. At the IOR, he directs also the Tumor Biology and Experimental Therapeutics Program – an interdisciplinary basic and translational research program on prostate cancer and other epithelial tumors spanning from genomics and molecular biology to experimental therapeutics, preclinical pharmacology and early phase clinical trials.

José Luis Fernández-Luna, Ph.D.

José Luis Fernández-Luna is currently coordinator of the Molecular Genetics Unit at the Valdecilla University Hospital and Head of the Cell Signaling and Therapeutic Targets Laboratory al the IFIMAV Institute (Santander, Spain).

He obtained his Ph.D. at the Complutense University of Madrid and was a NATO postdoctoral fellow at Washington University School of Medicine in St. Louis (MO, USA). In 1990 he moved to Santander where he established a group focused on the mechanisms that regulate apoptosis of cancer cells, making numerous scientific contributions to myeloproliferative diseases and solid tumors. Now he is leading a multidisciplinary group of molecular biologists, bioinformaticians, oncologists and surgeons involved in the study of cancer stem cells. They are defining the molecular components that control the differentiation and migration of cancer stem cells, mainly isolated from glioblastoma and colon cancer specimens, and screening novel compounds able to attack this population of cells with tumorigenic capacity.

Patrick J. Grohar, M.D., Ph.D.

Patrick J. Grohar is currently Associate Professor, Program in Skeletal Disease and Tumor Microenvironment, Center for Cancer and Cell Biology at Van Andel Research Institute (VARI). In addition to his appointment in VARI’s Center for Cancer and Cell Biology, Dr. Grohar maintains a clinical presence in the department of hematology/oncology at Spectrum Health Helen DeVos Children’s Hospital, where he is a member of the sarcoma team. He also has an academic appointment at Michigan State University in the Department of Pediatrics.

Dr. Grohar received his B.S. in chemistry from Villanova University followed by his Ph.D. in chemistry and his M.D. from Wayne State University in Detroit, Michigan. He then completed a residency at Johns Hopkins University followed by fellowship training in pediatric hematology oncology at Johns Hopkins and the National Cancer Institute, where he also served as a junior faculty member. After NCI, he joined the faculty at Vanderbilt University as an assistant professor of pediatrics before arriving at Van Andel Research Institute as an associate professor in July 2015.

The focus of Dr. Grohar’s research is on drug development for pediatric sarcomas and in particular the Ewing’s sarcoma family of tumors (ESFT). The major emphasis is on the identification and characterization of small molecule inhibitors of the EWS-FLI1 transcription factor for the treatment of Ewing’s sarcoma. The goal is to identify compounds that reverse the activity of this potent oncogene. In addition, Dr. Grohar studies the molecular biology of EWS-FLI1 mediated transcription as well as the identification and characterization of novel molecular targets for ESFT.

Alberto Ocaña, M.D., Ph.D.

Alberto Ocaña is a medical oncologist with experience in drug development and molecular biology. He is currently the medical director of the translational research unit at the Albacete University Hospital in Spain.

He obtained his Ph.D. in the field of tyrosine kinase inhibitors at the Salamanca Cancer Research Centre (CIC). Alberto trained in molecular biology at Vall d´Hebron Hospital, Barcelona under the supervisión of Dr. J. Baselga and in drug development and design of clinical studies at Princess Margaret Hospital in Toronto, Canada under the supervisión of Dr. Ian Tannock. He has more than 50 published articles in scientific journal like Oncogene, Clinical Cancer Research, Journal of Clinical Oncology, Journal of the National Cancer Institute or Annals of Oncology. He is also the medical coordinator of the early development program for the Spanish Breast Cancer Research Group (GEICAM).

Atanasio Pandiella, M.D., Ph.D.

Atanasio Pandiella is the Vicedirector of the Centro de Investigación del Cáncer (CIC, Salamanca, Spain) and Head of the Translational Oncopharmacology Laboratory, devoted to the optimization of drugs for the treatment of several neoplastic diseases.

Atanasio obtained his medical degree in 1983 at the University of Santiago de Compostela, Spain, and in 1987 his Ph.D. degree by the same University. After four years as a postdoctoral fellow in Milan working on signaling by growth factors under the direction of Prof. J. Meldolesi, he moved to the Memorial Sloan Kettering in New York where he extended his experience in this field under the direction of Prof. Joan Massagué.

After coming back to Spain, Dr. Pandiella has been involved in the study of how growth factors and their receptors participate in the generation of pro-oncogenic signals. This aspect of the research has been the basis of various translational studies in breast cancer and multiple myeloma. He also collaborates with clinical oncologists in the development of novel therapies in cancer. These collaborations have been able to settle several clinical trials using novel antitumoral therapies.

Jesús M. Paramio, Ph.D.

Jesús M. Paramio is currently the Director of the Molecular Oncology Unit at CIEMAT (Center for Energy, Environment and Technology Research) in Madrid (Spain).

He obtained his Ph.D. in Biology at the University Autonoma of Madrid and was a postdoctoral fellow at the Medical Sciences Institute in the University of Dundee and at the National Institute of Dental and Craniofacial Research of the NIH (Bethesda USA). He has more than 70 articles published in international scientific journals and is co-author of four patents for the genomic prognostic signatures of human cancers.

Dr. Paramio laboratory is focused on the generation of different mouse models through different genetic manipulation approaches affecting different tumor suppressor genes (Rb family, p53, Pten) or oncogenes (Akt) in certain epithelial tissues. These models were specifically designed to mimic different types of human cancer. More recently, his lab has focused on the identification of genomic alterations in human and mouse samples in order to validate the mouse models as preclinical tools for the study of experimental new therapeutics in cancer and the characterization of possible cancer stem cells in human and rodent specimens.

José Portugal, Ph.D.

José Portugal is Senior Research Scientist at the IBMB-CSIC in Barcelona, Spain. His research, focused on the interactions between antitumor drugs and DNA, seeks to examine the molecular and cellular bases of specific recognition.

José Portugal received his PhD in Biology from the University of Barcelona, Spain in 1983. He was a post-doc at the University of Cambridge, UK (1985-87), and he was appointed Lecturer in Biochemistry at the University of Barcelona (1987-1992). From 1992, he is a member of the Institute of Molecular Biology-CSIC in Barcelona.

His work aims at understanding the mechanisms used by DNA-binding drugs to inhibit transcription both in vitro and in vivo, and how changes in the transcriptome of cancer cells commit them to die. To this end, he analyzes the sequence-specific DNA binding of new antitumor drugs, including the effects of mithramycin analogues, on DNA-protein interactions during the transcription of oncogenes and tumor suppressors.

Jürgen Rohr, Ph.D.

Jürgen Rohr took his current position as Full Professor at the College of Pharmacy of the University of Kentucky in 2002, where he is currently the Director of the Division of Drug Discovery.

Jürgen Rohr graduated from the University of Göttingen, Germany, in 1984, with a Ph.D. in Organic Chemistry (major) and Microbiology (minor). He was post-doc in Prof. Heinz Floss’ laboratory at the Department of Chemistry of the Ohio-State-University, Columbus, Ohio, USA, until 1987. Before joining University of Kentucky, Dr. Rohr was Assistant Professor at the Department of Chemistry of the University of Göttingen, Germany, and Associate Professor at the Department of Pharmaceutical Sciences of the Medical University of South Carolina, Charleston, SC, USA.

His research interests span isolation and structure elucidation of natural products, biosynthetic studies of microbial natural products, combinatorial biosynthesis and enzymology, with focus on polyketides and more recently on enzymatic total syntheses.